Inhibiting the Mammalian Target of Rapamycin Blocks the Development of Experimental Cerebral Malaria
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Malaria is an infectious disease caused by parasites of several Plasmodium spp. Cerebral malaria (CM) is a common form of severe malaria resulting in nearly 700,000 deaths each year in Africa alone. At present, there is no adjunctive therapy for CM. Although the mechanisms underlying the pathogenesis of CM are incompletely understood, it is likely that both intrinsic features of the parasite and the human host's immune response contribute to disease. The kinase mammalian target of rapamycin (mTOR) is a central regulator of immune responses, and drugs that inhibit the mTOR pathway have been shown to be antiparasitic. In a mouse model of CM, experimental CM (ECM), we show that the mTOR inhibitor rapamycin protects against ECM when administered within the first 4 days of infection. Treatment with rapamycin increased survival, blocked breakdown of the blood-brain barrier and brain hemorrhaging, decreased the influx of both CD4+and CD8+T cells into the brain and the accumulation of parasitized red blood cells in the brain. Rapamycin induced marked transcriptional changes in the brains of infected mice, and analysis of transcription profiles predicted that rapamycin blocked leukocyte trafficking to and proliferation in the brain. Remarkably, animals were protected against ECM even though rapamycin treatment significantly increased the inflammatory response induced by infection in both the brain and spleen. These results open a new avenue for the development of highly selective adjunctive therapies for CM by targeting pathways that regulate host and parasite metabolism. IMPORTANCE Malaria is a highly prevalent infectious disease caused by parasites of several Plasmodium spp. Malaria is usually uncomplicated and resolves with time; however, in about 1% of cases, almost exclusively among young children, malaria becomes severe and life threatening, resulting in nearly 700,000 deaths each year in Africa alone. Among the most severe complications of Plasmodium falciparum infection is cerebral malaria with a fatality rate of 15 to 20%, despite treatment with antimalarial drugs. Cerebral malaria takes a second toll on African children, leaving survivors at high risk of debilitating neurological defects. At present, we have no effective adjunctive therapies for cerebral malaria, and developing such therapies would have a large impact on saving young lives in Africa. Here we report results that open a new avenue for the development of highly selective adjunctive therapies for cerebral malaria by targeting pathways that regulate host and parasite metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 1×
“The evolutionarily conserved serine/threonine kinase mammalian target of rapamycin (mTOR) plays a central role in regulating the outcome of antigen recognition in the adaptive immune system (24).”
BackgroundHeme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria
Pamplona, A., Ferreira, A., Balla, J., Jeney, V., Balla, G., Epiphanio, S., Chora, Â., Rodrigues, C. D., Gregoire, I. P., Cunha-Rodrigues, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1586 · Cited by 560 · cited 2×
“In support of this, Hmox1, which is induced in response to oxidative stress and protects against ECM (37), was unexpectedly downregulated in the brains, but not the spleens, of PbA-infected mice treated with rapamycin, suggesting that rapamycin protects from ECM by limiting oxidative stress events proximal to the indu…”
BackgroundMyelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis
Kim, J. V., Kang, S. S., Dustin, M. L., & McGavern, D. B. (2009) · Nature · doi:10.1038/nature07591 · Cited by 326
Brain microvessel cross‐presentation is a hallmark of experimental cerebral malaria
Howland, S. W., Poh, C. M., Gun, S. Y., Claser, C., Malleret, B., Shastri, N., Ginhoux, F., Grotenbreg, G. M., & Rénia, L. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202273 · Cited by 150
Cited by
Normalizing the environment recapitulates adult human immune traits in laboratory mice
Beura, L. K., Hamilton, S. E., Bi, K., Schenkel, J. M., Odumade, O. A., Casey, K. A., Thompson, E. A., Fraser, K. A., Rosato, P. C., Filali-Mouhim, A., et al. (2016) · Nature · doi:10.1038/nature17655 · Cited by 1,072
Swanson, P. A., Hart, G. T., Russo, M. V., Nayak, D., Yazew, T., Peña, M., Khan, S. M., Janse, C. J., Pierce, S. K., & McGavern, D. B. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1006022 · Cited by 125
Self-citationZhou, R., Sun, X., Li, Y., Huang, Q., Qu, Y., Mu, D., & Li, X. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.020 · Cited by 21
Metadata
- Authors
- Gordon, E. B., Hart, G. T., Tran, T. M., Waisberg, M., Akkaya, M., Skinner, J., Zinöcker, S., Pena, M., Yazew, T., Qi, C.-F., Miller, L. H., & Pierce, S. K.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2015-07
- Volume
- 6
- Issue
- 3
- Pages
- e00725-e00725
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- OpenAlex
- W1883587302
- Cited by
- 52
- References
- 4
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.